Engflag

Chenodeoxycholic Acid

Quick links to important sections

Chenodeoxycholic Acid

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Chenodeoxycholic Acid

Quick Facts

Property Description
Active ingredient Chenodeoxycholic Acid (Chenodiol)
Form Oral tablet
Pharmacological class Gallstone Solubilizing Agent, Bile Acid Preparation
Common use Dissolution of cholesterol gallstones
Origin Naturally occurring (Primary Bile Acid)

What Type of Medicine is Chenodeoxycholic Acid (Chenodiol)?

Chenodeoxycholic Acid (CDCA), often referenced by its INN Chenodiol, is classified as a primary bile acid preparation and a potent gallstone solubilizing agent. This substance is a metabolite, meaning it is one of the two main bile acids naturally synthesized by the human body from cholesterol, granting it a unique physiological familiarity. As a pharmaceutical agent, it falls under the broader pharmacological category of Gastrointestinal Agents. It is utilized as an agent for modifying bile composition, serving as a fundamental metabolic therapy.

Is Chenodeoxycholic Acid a Natural Compound, and What is its Form?

Chenodeoxycholic Acid is a naturally occurring substance in human physiology, recognized as an essential primary bile acid. The medicine is consistently presented as a single-ingredient product, typically available as an oral tablet for systemic administration. This solid oral form ensures the Active Pharmaceutical Ingredient (API), which is chemically a C24-steroid, is absorbed to directly influence liver and biliary function. Unlike many combination therapies, its utility rests on the specific metabolic action of the bile acid itself, facilitating a focused approach to managing biliary cholesterol.

What is the Primary Function of this Bile Acid Preparation?

The primary general function of Chenodeoxycholic Acid is its action as a cholelitholytic agent, giving it the recognized ability to dissolve cholesterol stones. This general benefit is achieved by influencing hepatic output. The compound works by reducing the liver's secretion of cholesterol into the bile, and by simultaneously changing the chemical makeup of the bile itself. By reducing the biliary cholesterol saturation, the medicine creates an environment where cholesterol crystals cannot form and existing deposits can gradually break down, addressing the metabolic imbalance that causes them. Its typical use involves providing a non-surgical option for patients with radiolucent cholesterol gallstones.

Regulatory References

  1. NIH LiverTox

What side effects are possible with Chenodeoxycholic Acid?

Possible Side Effects and Safety Information

Chenodeoxycholic Acid (Chenodiol) has an official safety profile structured around potential adverse reactions and specific regulatory constraints detailed in government labeling. The most frequently documented adverse reactions primarily involve the gastrointestinal system and are classified as Common in regulatory documents (occurring in at least 1 out of 100 people). These common effects include diarrhea, abdominal pain, headache, constipation, muscular weakness, hypertension, and upper respiratory tract infection.

Serious Adverse Reactions and Systemic Concerns

The most clinically significant safety concern is Hepatotoxicity, which is associated with elevations in serum aminotransferases (ALT and AST). These abnormal liver test values are also officially classified as Common . Regulatory text specifies that these elevations are often dose-related and have been observed at the beginning of treatment. Severe hepatic failure is noted as a possibility in the context of mandatory monitoring and requires immediate consideration for treatment cessation.

Population and Regulatory Safety Constraints

Specific regulatory constraints exist for certain patient populations. The medicine is restricted in individuals with severe pre-existing liver disease and specific bile duct abnormalities, as they are documented to be at increased risk for severe hepatotoxicity. Furthermore, women of childbearing potential are advised to use effective contraception during therapy, as the medicine is not recommended during pregnancy.

Overdose and Emergency Response

The official regulatory profile for Chenodeoxycholic Acid overdose details specific clinical manifestations and mandated emergency actions. Documented symptoms associated with overexposure include gastrointestinal distress, commonly presenting as diarrhea, nausea, abdominal pain, and sometimes dizziness.

Overdose can lead to a critical, toxic state primarily affecting the liver. The regulatory documents define severe overexposure by objective measures: treatment must be interrupted if liver transaminase (ALT/AST) levels exceed three times the upper limit of normal or if total bilirubin exceeds two times the upper limit of normal.

Immediate action is required if an overdose is suspected. Urgent medical attention must be sought immediately. In cases where severe systemic symptoms occur—such as trouble breathing, seizure, collapse, or inability to be awakened—the official guidance mandates calling emergency services (e.g., 911) or contacting a Poison Control center. There is no specific antidote known for Chenodeoxycholic Acid overdose; management focuses on providing symptomatic and supportive treatment. No special population-specific overdose considerations are currently documented in official labeling.

Therapeutic Uses of Chenodeoxycholic Acid

Chenodeoxycholic Acid (CDCA) is a naturally occurring bile acid with two main therapeutic domains. It is utilized in clinical contexts where symptomatic support is required, primarily in managing a rare genetic disorder and in addressing gallstone formations.

Managing Cerebrotendinous Xanthomatosis (CTX)

This medication plays a role in managing CTX, a rare lipid storage disorder. It is used to help address symptom clusters that may become intense or disruptive and interfere with daily comfort. The application of this therapy generally contributes to managing the overall symptom load and supports functional stability during periods when symptoms are more noticeable.

Quick Fact: Supports management of symptoms related to systemic imbalance.

Addressing Symptom Clusters Related to Gallstones

CDCA is used in conditions involving acute episodes, specifically to address issues related to gallstone formation for patients who require supportive management. When applied in clinical settings involving acute or unstable symptom patterns, it is intended to support day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Chenodeoxycholic Acid — Official Regulatory Information

The eligibility profile for Chenodeoxycholic Acid is defined by regulatory bodies through specific rules governing patient populations, age, and pre-existing conditions.

Contraindicated Populations

Use is strictly contraindicated for several groups. Patients must not use this medicine if they have pre-existing liver disease (including known hepatocyte dysfunction) or bile duct abnormalities such as obstruction. It is also contraindicated for patients with acute gallstone complications (e.g., acute cholecystitis) or if they have radiopaque (calcified) gallstones. Additionally, it is contraindicated in women who are pregnant.

Age and Conditional Use Rules

Population Group Eligibility Status
Adults with CTX Allowed, based on official labeling.
Pediatric Population Allowed for CTX in children and adolescents; safety is not established in neonates less than one month of age.
Women of Childbearing Potential Use is restricted and requires the concurrent use of effective contraception.
Renal Impairment No data are available; patients require careful monitoring.

Eligibility also requires that treatment be interrupted if liver transaminase levels become significantly elevated above the normal limit, underscoring the necessity of pre-existing normal hepatobiliary function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Chenodeoxycholic Acid (CDCA) primarily through two mechanisms: substances that reduce its absorption and those that counteract its therapeutic effect.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with Bile Acid Sequestering Agents (e.g., Cholestyramine, Colestipol) and Aluminum-Based Antacids reduces the intestinal absorption of CDCA, which can diminish its overall exposure and effectiveness. To mitigate this effect, a strict separation of administration time is required, typically ranging from two to six hours apart, depending on the agent.

Conversely, certain medications are documented to antagonize CDCA's action. Estrogen-containing products and the lipid-lowering drug Clofibrate are noted to increase the secretion of cholesterol into bile, thereby counteracting the cholelitholytic efficacy of CDCA. Additionally, immunosuppressants like Ciclosporin and Sirolimus may reduce the body's natural synthesis of CDCA, which leads to restrictions on their concomitant use.

Finally, CDCA can affect the pharmacodynamics of Coumarin derivatives (e.g., Warfarin), requiring clinical monitoring of prothrombin time due to the documented risk of unexpected prolongation.

Mechanism of Action

Chenodeoxycholic Acid (CDCA) acts primarily on the hepatic system by modulating the synthesis and secretion of cholesterol into the bile. This action is mediated, in part, by regulatory effects on the rate-limiting enzyme HMG-CoA reductase, which controls endogenous cholesterol production. This core mechanism alters the biliary composition, resulting in a reduction of the cholesterol saturation index—a measure of the bile's physical capacity to maintain cholesterol in solution.

Simultaneously, CDCA integrates directly into the circulating bile acid pool, increasing its relative concentration compared to other endogenous bile acids. This compositional modification enhances the micellar capacity of the bile, thereby increasing its intrinsic ability to solubilize cholesterol. This shift in the bile acid-to-cholesterol ratio modifies the physicochemical conditions that favor cholesterol crystallization and subsequent aggregation within the gallbladder and biliary system.

Dosage and Administration Information

How to Use Chenodeoxycholic Acid

The administration of Chenodeoxycholic Acid follows established protocols that define the specific route, frequency, and duration patterns for its distinct uses. The medicine is supplied as a 250 mg oral tablet or capsule and is administered exclusively via the oral route. It may be taken with or without food.

Official Dosing and Frequency Patterns

Indication Dosing Regimen Frequency Pattern Duration and Adjustment
Cerebrotendinous Xanthomatosis (CTX) Starting dose of 750 mg per day, not exceeding 1,000 mg per day. Administered in three divided doses daily. Used as long-term replacement therapy.
Gallstone Dissolution Weight-based, ranging from 13 to 16 mg/kg/day. Administered in two divided doses daily (morning and night). Treatment is typically limited to 24 months and is discontinued if no response is observed by 18 months.

Administration Requirements

Tablets are intended to be swallowed whole. For instances where swallowing is difficult, the contents of the capsule form can be mixed with an 8.4% sodium bicarbonate solution.

Regarding missed doses, the standard protocol involves skipping the missed dose and resuming the regular schedule; a double dose is not taken to compensate. For older adults (65 years and over), established clinical guidelines indicate that dose adjustment is not necessary. Pediatric administration for CTX follows a specific weight-based regimen, typically starting at 5 mg/kg/day in three divided doses. These administration parameters define the standardized use of Chenodeoxycholic Acid.

Recent Clinical Evidence

Chenodeoxycholic Acid: Recent Clinical Evidence

Chenodeoxycholic acid (CDCA), or chenodiol, is a naturally occurring bile acid used therapeutically for two primary indications: the dissolution of certain gallstones and the treatment of the rare genetic disorder Cerebrotendinous Xanthomatosis (CTX).

Efficacy in Cerebrotendinous Xanthomatosis (CTX)

Recent clinical research has focused on CDCA’s role as a replacement therapy for CTX, a progressive lipid storage disease caused by a deficiency in the enzyme sterol 27-hydroxylase. This deficiency leads to the abnormal buildup of cholesterol metabolites like cholestanol in various tissues, including the brain and tendons.

  • RESTORE Trial: A 24-week, randomized, double-blind, placebo-controlled crossover trial was conducted in adult patients with CTX. The primary finding demonstrated that CDCA treatment was associated with a statistically significant reduction in plasma cholestanol and urine 23S-pentol (cholesterol metabolites that are markedly increased in CTX) compared to placebo.
  • Therapeutic Effect: By replacing the deficient bile acid, CDCA helps to normalize the bile acid synthesis pathway, which is thought to reduce the accumulation of toxic metabolites that drive disease progression.

Role in Cholesterol Gallstone Dissolution

CDCA was historically used and is still indicated for the oral dissolution of small, radiolucent (non-calcified) cholesterol gallstones in patients for whom surgery may carry increased risk. The therapy works by decreasing the saturation of cholesterol in bile, promoting the gradual dissolution of stones. However, recurrence rates may be high after treatment discontinuation, and its use is often reserved for selected patients. The efficacy of CDCA for gallstone dissolution varies widely, with complete dissolution rates reported between 15% to 30% in controlled trials.

Safety Profile Summary

The most common adverse effect associated with CDCA treatment across its indications is diarrhea. Other reported side effects include abdominal pain, constipation, headache, and reversible elevations in liver enzymes (transaminases). Due to the risk of liver toxicity, monitoring of liver function tests is recommended for individuals on this treatment.

How should Chenodeoxycholic Acid be stored and disposed of?

Storage and Disposal of Chenodeoxycholic Acid

Chenodeoxycholic Acid (Chenodiol) must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). Short excursions are permitted up to 30 C.

Storage Conditions

Requirement Condition
Temperature 20 C to 25 C (Controlled Room Temp)
Container Keep the container tightly sealed in a dry, cool, and well-ventilated area.
Child Safety Store out of the sight and reach of children.

Disposal

Any unused or expired Chenodeoxycholic Acid product must be disposed of in accordance with national and local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Chenodeoxycholic Acid found in:

A-Z Index: